Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice. (August 2019) - Kassner, U.; Hollstein, T.; Schumann, F.; Grenkowitz, T.; Scharnagl, H.; März, W.; Steinhagen-Thiessen, E.